Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (limits study) ... The Liquemin in Myocardial Infarction During Thrombolysis With Saruplase (LIMITS) study was instituted to evaluate and characterize the effect of a prethrombolytic heparin bolus (5,000 IU) on the efficacy and safety of saruplase in patients...
Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarctionWe examined in patients with acute myocardial infarction (AMI) the pharmacokinetics of saruplase, an unglycosylated, single chain, urokinase-type plasminogen activator (rscu-PA) by measuring urokinase-type plasminogen activator (u-PA) antigen and total u-PA activity,...
Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarctionBACKGROUND: The recombinant unglycosylated single chain urokinase-type plasminogen activator saruplase is cleared for a large part by the liver....
Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the compass equivalence trial fn1fn1this study was supported by grünenthal gmbh, the manufacturer of saruplase. ... This study sought to demonstrate the equivalence of saruplase and streptokinase in terms of 30-day mortality.Background....
